Need professional-grade analysis? Visit stockanalysis.com
$2.86B
13.83
182
N/A
Catalyst Pharmaceuticals Inc (CPRX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $25.64, down 2.36% from the previous close.
Over the past year, CPRX has traded between a low of $19.13 and a high of $26.31. The stock has gained 10.9% over this period. It is currently 34.0% above its 52-week low.
Catalyst Pharmaceuticals Inc has a market capitalization of $2.86B, with a price-to-earnings ratio of 13.83.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Side-by-side comparison against top Healthcare peers.